The fall of vaccination campaign, necessary to contain the epidemic this winter, struggles to convince eligible people. Decoders take stock of which is the right to which vaccine.
by decoders
Almost two years after their arrival, vaccines against the COVVI-19 are no longer a reflex for a majority of French people, as weariness seems to have settled in the spirits after two years to live according to the circulation of virus. Even if the Minister of Health, François Braun, and government spokesman Olivier Véran called the French eligible to vaccinate, this fall campaign did not benefit from a communication as important as the previous ones. The arrival of new vaccines and the application of multiple eligibility rules have also complicated readability.
relatives of people at risk are eligible
The vaccination campaign launched on October 3 lists the populations most at risk of developing serious forms of COVID-19, as well as the flu in a seasonal way:
- People aged 60 and over;
- Residents of accommodation establishments for dependent elderly people (EHPAD) and long -term care units;
- Immunode -depressed people;
- Pregnant women;
- People in regular contact with people at risk.
These categories seem to target a small part of the population, but in reality, this new vaccination recall is accessible to anyone frequent a person at risk. “A young person, without comorbidity, who regularly sees relatives in the target is therefore eligible”, recalls a circular of November 21 of the Directorate General of Health.
Like previous campaigns, it authorizes a three-month tighter interval between two injections for the most fragile audiences (over 80 years, immunocompromised, etc.), while the rest of the population at risk must Wait six months after the last injection or infection at the COVVI-19.
Mainly closed vaccination centers, but vaccination remains accessible by city medicine: with a general practitioner, in pharmacy or in a nursing office.
vaccines adapted to variants
Current vaccines are mostly bivalent vaccines with messenger RNA capable of targeting both the original strain of the virus and omicron (BA.1) or variants close to omicron (BA.4 and BA.5). These two bivalent vaccines offer better protection against variants in circulation in recent months and are particularly recommended for people with comorbidity factors exposing them to a serious form of COVID-19.
As before, the Moderna vaccine (Spikevax) remains reserved for people aged 30 and over due to the risk of myocarditis in the youngest subjects. The under 30s will therefore be able to benefit from one of the two new bivalent vaccines of Pfizer-Biontech, which are just as protective.
At 1 er December, just over 1.9 million French people had received a dose of recall with the available bivalent vaccines: 9.6 % of the 70s and over benefited from it, But only 6.5 % of 60-69 year olds.